ClinicalTrials.gg
CompletedNCT01549587OHMOMUpdated Apr 21, 2023Results posted

Oral Hygiene and Maternity Outcomes Multicenter Study (OHMOM)

An interventional study of 0.243% sodium fluoride and toothbrush in Gingivitis and Pregnancy, sponsored by Procter and Gamble. Completed at 2 sites in United States. Open to female participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2023-04-21.

Sponsored by Procter and Gamble · Not applicable, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
746
Allocation
Randomized
Ages
18 Years and older
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 23 studies testing Tin Fluorides in Gingivitis — 1 open to participants now, 3 under way, none of them phase 3. Tin Fluorides · Gingivitis.

Enrollment
Largest of 23
746 · median 115
Started
2012
the only one that year
No phase
10 of 23
none open now
Registered
1st of 23
by date
Lead sponsor
9 of 23
Procter and Gamble

Among the 23 studies testing Tin Fluorides in Gingivitis, this one has the largest enrollment, is the only one that started in 2012, is one of 10 with no phase, and was the 1st registered.

Gingivitis

631 studies on the registry are indexed under Gingivitis; 107 are open to participants now.

Browse Gingivitis studies →

Open to participants now

1 of the 23 studies testing Tin Fluorides in Gingivitis is open now. Recruiting first, the newest first:

About Tin Fluorides

No approval found in the FDA or EMA files read. How studies give it is on its page →

Who these studies take

Of the 53 Gingivitis studies recruiting now, 15 (28%) set no upper age limit and 36 (68%) stop at 75 or younger; 11 take children under 18; 35 take healthy volunteers.

This study: 18 Years and older · female · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 23 studies testing Tin Fluorides in Gingivitis, or all of them as a file.
02

Study summary

This study will track changes in oral health in pregnant women. Subjects will be assigned to either regular oral care or advanced oral care and be given oral care products to use until they deliver. A comparison between the two groups (regular and advanced oral care) will be made to see if the oral care products impacted oral health and maternity variables.

03

Conditions studied

  • Gingivitis
  • Pregnancy

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Female
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • provide written prior to participation and be given a signed copy of the informed consent form;
  • be at least the age of legal consent;
  • be between 8 and 24 weeks of pregnancy;
  • have at least 20 natural teeth;
  • have moderate-to-severe gingivitis during pregnancy, including at least 30 intraoral sites with evidence of marginal gingival bleeding.

Exclusion criteria

Exclusion Criteria:

  • evidence of multiple gestations;
  • history of infection, AIDS, disease, or diabetes other than gestational diabetes;
  • indication for use of antibiotic pre-medication prior to dental procedures;
  • systemic or therapy within 1 month of Baseline;
  • severe periodontal disease, rampant untreated dental caries, or other oral conditions that necessitate immediate dental care;
  • ongoing dental care that in the opinion of the investigator could impact study participation;
  • a history of allergies or to mouth rinse products containing CPC;
  • any disease or condition that in the opinion of the investigator could interfere with the safe completion of the study;
  • randomization to a treatment in study 2011001 during a prior pregnancy.
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Investigator)
Enrollment
746 participants (actual)

Study arms

  • Active comparator
    Regular Oral Hygiene

    toothpaste, toothbrush and dental floss

    Drug: 0.243% sodium fluoride · Device: toothbrush · Device: dental floss

  • Experimental
    Advanced Oral Hygiene plus counseling

    toothpaste, toothbrush, mouth rinse and dental floss plus specialized education

    Drug: 0.454% stannous fluoride · Device: toothbrush · Drug: 0.07% Cetylpyridinium chloride · Device: dental floss

Interventions

  • dentifrice: brush thoroughly twice daily

    Also known as: Crest® Cavity Protection toothpaste

  • Devicetoothbrush

    brush thoroughly twice daily

    Also known as: Oral-B® Indicator toothbrush, regular, soft

  • Devicedental floss

    floss the whole mouth once daily

    Also known as: Oral-B® Essentials dental floss

  • dentifrice: twice daily brush thoroughly for 2 minutes

    Also known as: Crest® Pro-Health toothpaste

  • Devicetoothbrush

    twice daily brush thoroughly for 2 minutes

    Also known as: Oral-B® ProfessionalCare Series 1000 toothbrush, Oral-B® Precision Clean brush head

  • mouth rinse: rinse with 20 mL of mouth rinse for 30 seconds twice daily

    Also known as: Crest® Pro-Health Multi-Protection Mouth Rinse

  • Devicedental floss

    floss the whole mouth once daily

    Also known as: Glide® Pro-Health Deep Clean dental floss

06

What researchers measure

Primary outcomes

  1. Change From Baseline in Löe-Silness Gingivitis Index

    Score Criteria 0 Normal gingiva. 1. Mild inflammation - slight change in color, slight edema. No bleeding on probing. 2. Moderate inflammation - redness, edema, and glazing. Bleeding on probing. 3. Severe inflammation - marked redness, edema. Ulceration. Tendency to spontaneous bleeding.

    Time frame: 3 months

  2. Change From Baseline in Löe-Silness Gingivitis Index

    Score Criteria 0 Normal gingiva. 1. Mild inflammation - slight change in color, slight edema. No bleeding on probing. 2. Moderate inflammation - redness, edema, and glazing. Bleeding on probing. 3. Severe inflammation - marked redness, edema. Ulceration. Tendency to spontaneous bleeding.

    Time frame: 2 months

  3. Change From Baseline in Löe-Silness Gingivitis Index

    Score Criteria 0 Normal gingiva. 1. Mild inflammation - slight change in color, slight edema. No bleeding on probing. 2. Moderate inflammation - redness, edema, and glazing. Bleeding on probing. 3. Severe inflammation - marked redness, edema. Ulceration. Tendency to spontaneous bleeding.

    Time frame: 1 month

Secondary outcomes

  1. Gestational Age (Weeks)

    log\[42.9-gestational age\]

    Time frame: At delivery

Other outcomes

  1. Neonate Birth Weight (Grams)

    Time frame: At delivery

  2. Preterm Birth (Gestational Age < 37 Weeks)

    Time frame: At delivery

07

Results

Posted Oct 19, 2020

Participant flow

Participant flow — Overall Study
MilestoneRegular Oral HygieneAdvanced Oral Hygiene Plus Counseling
Started373373
Completed334336
Not completed3937

Outcome measures

PrimaryChange From Baseline in Löe-Silness Gingivitis Index

Score Criteria 0 Normal gingiva. 1. Mild inflammation - slight change in color, slight edema. No bleeding on probing. 2. Moderate inflammation - redness, edema, and glazing. Bleeding on probing. 3. Severe inflammation - marked redness, edema. Ulceration. Tendency to spontaneous bleeding.

Time frame:
3 months
Reported as:
Least squares mean · score on a scale
Change From Baseline in Löe-Silness Gingivitis Index
score on a scaleRegular Oral HygieneAdvanced Oral Hygiene Plus Counseling
Change From Baseline in Löe-Silness Gingivitis Index0.141 ± 0.00460.154 ± 0.0046
PrimaryChange From Baseline in Löe-Silness Gingivitis Index

Score Criteria 0 Normal gingiva. 1. Mild inflammation - slight change in color, slight edema. No bleeding on probing. 2. Moderate inflammation - redness, edema, and glazing. Bleeding on probing. 3. Severe inflammation - marked redness, edema. Ulceration. Tendency to spontaneous bleeding.

Time frame:
2 months
Reported as:
Least squares mean · score on a scale
Change From Baseline in Löe-Silness Gingivitis Index
score on a scaleRegular Oral HygieneAdvanced Oral Hygiene Plus Counseling
Change From Baseline in Löe-Silness Gingivitis Index0.124 ± 0.00440.137 ± 0.0045
PrimaryChange From Baseline in Löe-Silness Gingivitis Index

Score Criteria 0 Normal gingiva. 1. Mild inflammation - slight change in color, slight edema. No bleeding on probing. 2. Moderate inflammation - redness, edema, and glazing. Bleeding on probing. 3. Severe inflammation - marked redness, edema. Ulceration. Tendency to spontaneous bleeding.

Time frame:
1 month
Reported as:
Least squares mean · score on a scale
Change From Baseline in Löe-Silness Gingivitis Index
score on a scaleRegular Oral HygieneAdvanced Oral Hygiene Plus Counseling
Change From Baseline in Löe-Silness Gingivitis Index0.112 ± 0.00450.125 ± 0.0045
SecondaryGestational Age (Weeks)

log\[42.9-gestational age\]

Time frame:
At delivery
Reported as:
Least squares mean · log weeks
Gestational Age (Weeks)
log weeksRegular Oral HygieneAdvanced Oral Hygiene Plus Counseling
Gestational Age (Weeks)1.3988 ± 0.033941.3271 ± 0.03403
Other pre-specifiedNeonate Birth Weight (Grams)
Time frame:
At delivery
Reported as:
Least squares mean · grams
Neonate Birth Weight (Grams)
gramsRegular Oral HygieneAdvanced Oral Hygiene Plus Counseling
Neonate Birth Weight (Grams)3095.97 ± 46.5883167.80 ± 45.955
Other pre-specifiedPreterm Birth (Gestational Age < 37 Weeks)
Time frame:
At delivery
Reported as:
Count of participants · Participants
Preterm Birth (Gestational Age < 37 Weeks)
ParticipantsRegular Oral HygieneAdvanced Oral Hygiene Plus Counseling
Preterm Birth (Gestational Age < 37 Weeks)3221

Adverse events

Collected over Participants were enrolled 8-24 weeks into pregnancy until delivery. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Regular Oral Hygiene0/373 (0%)79/373 (21.2%)353/373 (94.6%)
Advanced Oral Hygiene Plus Counseling0/373 (0%)75/373 (20.1%)329/373 (88.2%)
Most frequent serious events
Showing 10 of 71
Most frequent serious events
EventRegular Oral HygieneAdvanced Oral Hygiene Plus Counseling
PREMATURE DELIVERYPregnancy, puerperium and perinatal conditions27/37315/373
PRE-ECLAMPSIAPregnancy, puerperium and perinatal conditions21/37312/373
CHORIOAMNIONITISInfections and infestations14/37310/373
PREMATURE RUPTURE OF MEMBRANESPregnancy, puerperium and perinatal conditions9/3737/373
GESTATIONAL HYPERTENSIONPregnancy, puerperium and perinatal conditions8/3737/373
FOETAL GROWTH RESTRICTIONPregnancy, puerperium and perinatal conditions1/3737/373
PREMATURE LABOURPregnancy, puerperium and perinatal conditions6/3737/373
STILLBIRTHPregnancy, puerperium and perinatal conditions4/3733/373
VAGINAL HAEMORRHAGEReproductive system and breast disorders4/3733/373
BLOOD PRESSURE INCREASEDInvestigations3/3731/373
Most frequent other events
Showing 10 of 12
Most frequent other events
EventRegular Oral HygieneAdvanced Oral Hygiene Plus Counseling
STREPTOCOCCUS TEST POSITIVEInvestigations88/37394/373
ANAEMIABlood and lymphatic system disorders35/37341/373
PREMATURE DELIVERYPregnancy, puerperium and perinatal conditions40/37328/373
URINARY TRACT INFECTIONInfections and infestations27/37318/373
GESTATIONAL DIABETESPregnancy, puerperium and perinatal conditions25/37317/373
CHORIOAMNIONITISInfections and infestations24/37322/373
VULVOVAGINAL MYCOTIC INFECTIONInfections and infestations21/37324/373
PRE-ECLAMPSIAPregnancy, puerperium and perinatal conditions23/37315/373
NAUSEAGastrointestinal disorders18/37319/373
VOMITINGGastrointestinal disorders14/37319/373

Baseline characteristics

Age, Continuous
Age, Continuous(years)Regular Oral HygieneAdvanced Oral Hygiene Plus CounselingTotal
Mean27.6 ± 5.8927.4 ± 6.0127.46 ± 5.945
Sex: Female, Male
Sex: Female, Male(Participants)Regular Oral HygieneAdvanced Oral Hygiene Plus CounselingTotal
Female373373746
Male000
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Regular Oral HygieneAdvanced Oral Hygiene Plus CounselingTotal
American Indian202
Asian Oriential81523
Black260262522
Caucasian7677153
Hispanic131023
Asian Indian6410
Multi-racial8513
08

Study locations

2 sites
  • Center for Women's Reproductive Health
    Birmingham, Alabama 35294-0024, United States
  • Penn OB/Gyn and Associates
    Philadelphia, Pennsylvania 19104, United States
09

References and documents

Publications

  • Parry S, Jeffcoat M, Reddy MS, Doyle MJ, Grender JM, Gerlach RW, Tanna N, Geisinger ML, Geurs NC, Biggio J. Evaluation of an advanced oral hygiene regimen on maternity outcomes in a randomized multicenter clinical trial (Oral Hygiene and Maternity Outcomes Multicenter Study). Am J Obstet Gynecol MFM. 2023 Aug;5(8):100995. doi: 10.1016/j.ajogmf.2023.100995. Epub 2023 Apr 29. PubMed 37127210 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Feb 2012, a primary completion of Feb 2014 and a completion of Apr 2014. It does not say whether these dates are actual or estimated.

Results were first posted in Oct 2020, 6 years 8 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 28, 2012
First posted
Mar 9, 2012
Start
Feb 2012
Primary completionActual
Feb 2014
CompletionActual
Apr 2014
Results first posted
Oct 19, 2020
Last update
Apr 21, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 21, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01549587
Lead sponsor
Procter and Gamble
Responsible party
Sponsor
First posted
Mar 9, 2012
Start date
Feb 2012
Primary completion
Feb 2014
Completion
Apr 2014
Results posted
Oct 19, 2020
Last update
Apr 21, 2023

Study contacts

Marjorie Jeffcoat, DMD
principal investigator · School of Dentistry University of Pennsylvania
Michael Reddy, DMD, DMSc
principal investigator · School of Dentistry University of Alabama

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Tin Fluorides · Cetylpyridinium

Start the discussion